Machine-learning models identify cerebrospinal-fluid protein signatures for multiple-sclerosis activity and disability progression
Using Olink proteomics of 1,463 proteins in CSF and plasma from two prospective Swedish cohorts, the study trained prediction models for multiple-sclerosis diagnosis, 2-year disease activity and long-term disability worsening. Lower CSF neurofilament light (NfL) predicted absence of disease activity at two years (replication AUC 0.77). A stepwise model using 11 CSF proteins (CXCL13, LTA, FCN2, ICAM3, LY9, SLAMF7, TYMP, CHI3L1, FYB1, TNFRSF1B and NfL) predicted normalized age-related MS severity; subgroup classification AUCs in the replication cohort ranged from 0.88 to 0.90.
Technology: Stepwise logistic regression for diagnosis and disease activity; stepwise linear regression for long-term disability severity
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Using Olink proteomics of 1,463 proteins in CSF and plasma from two prospective Swedish cohorts, the study trained prediction models for multiple-sclerosis diagnosis, 2-year disease activity and long-term disability worsening.
- Still unknown: The study included 143 people with early-stage MS and 43 healthy controls across discovery and replication cohorts; the replication MS cohort had 51 participants. The 2-year disease-activity comparison in replication was especially small (45 with activity versus 5 without). The 11-protein severity model predicted observational disability scores rather than treatment benefit. The plasma severity model had only 12 eligible replication samples and performed less convincingly. These are cohort-level results, not a clinically validated diagnostic assay or independent replication by another research group.
- AI role: The study used statistical differential-expression testing to select disease-associated candidate proteins, then fitted logistic-regression models to predict MS diagnosis and 2-year disease activity and a linear-regression model to predict long-term normalized age-related MS severity. Stepwise feature selection produced the protein combinations; the frozen models were evaluated in a separate prospective cohort.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10616092/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 112 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.